

HEALTH PLAN POLICY	
Policy Title: Genetic Expression Profiling for Colorectal Cancer	Policy Number: MUM56 Revision: New
Department: Medical Management	Sub-Department: Utilization Management
Applies to Product Lines:	
<input type="checkbox"/> Medicaid	<input checked="" type="checkbox"/> USFHP
<input type="checkbox"/> Children's Health Insurance Plan	<input checked="" type="checkbox"/> Commercial Insured
<input checked="" type="checkbox"/> Health Insurance Exchange	<input type="checkbox"/> Non Insured Business
<input checked="" type="checkbox"/> Medicare	
Origination/Effective Date: 09/11/2019	
Reviewed Date(s):	Revision Date(s):

SCOPE:

This policy addresses genetic expression profiling (GEP) in patients potentially at risk for colorectal cancer (CRC).

DEFINITIONS AND ACRONYMS:

- Agency for Healthcare Quality & Research (AHRQ)
- Colorectal Cancer (CRC)
- Genetic Expression Profiling (GEP)
- National Comprehensive Cancer Network (NCCN) – alliance of 27 cancer centers.

POLICY:

This technique is investigational and not medically necessary.

RATIONALE:

Colorectal cancer is the third most common malignancy in the US, accounting for about 140,000 new cases per year with nearly 50,000 deaths. Routine screening has long been recommended by various professional societies without a lot of success. As a result, GEP for CRC has been promoted as a potentially preferred screening tool.

There are several genetic laboratories available that do multigenic panels, varying from five genes tests to over 50. Although results are variable, both the AHRQ & NCCN have not supported based on an absence of literature evidence the use of these GEP tests.

REFERENCES:

- NCCN 2018 Multigenic Assays for Determining adjuvant Chemotherapy
- AHRQ Black 2012 Use of GEP Assays
- ACS 2018 Noninvasive Screening Tests

HEALTH PLAN POLICY

Policy Title: Genetic Expression Profiling for Colorectal Cancer

Policy Number: MUM56
Revision: New


RELATED DOCUMENTS:

None



Nancy Horstmann
Chief Executive Officer Health Plans

10/15/19
Date



David Engleking, M.D.
Medical Director

10/15/19
Date

REVISION HISTORY:

Revision	Date	Description of Change	Committee
New	10/09/2019	Initial release.	Executive Leadership